Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Biliary Tract Neoplasms/*pathology ; Carcinoma, Hepatocellular/*pathology ; Contrast Media/*metabolism ; Liver Neoplasms/*pathology ; Magnetic Resonance Imaging/*methods; Biliary Tract Neoplasms/metabolism ; Carcinoma, Hepatocellular/metabolism ; Gadolinium DTPA/metabolism ; Humans ; Image Enhancement ; Liver Neoplasms/metabolism ; Retrospective Studies

This study aimed to assess the degree of differentiation of hepatocellular carcinoma (HCC) using Gd-EOB-DTPA-assisted magnetic resonance imaging (MRI) with T1 relaxometry. Thirty-three solitary HCC lesions were included in this retrospective study. This study's inclusion criteria were preoperative Gd-EOB-DTPA-assisted MRI of the liver and a histopathological evaluation after hepatic tumor resection. T1 maps of the liver were evaluated to determine the T1 relaxation time and reduction rate between the native phase and hepatobiliary phase (HBP) in liver lesions. These findings were correlated with the histopathologically determined degree of HCC differentiation (G1, well-differentiated; G2, moderately differentiated; G3, poorly differentiated). There was no significant difference between well-differentiated (950.2 ± 140.2 ms) and moderately/poorly differentiated (1009.4 ± 202.0 ms) HCCs in the native T1 maps. After contrast medium administration, a significant difference (p ≤ 0.001) in the mean T1 relaxation time in the HBP was found between well-differentiated (555.4 ± 140.2 ms) and moderately/poorly differentiated (750.9 ± 146.4 ms) HCCs. For well-differentiated HCCs, the reduction rate in the T1 time was significantly higher at 0.40 ± 0.15 than for moderately/poorly differentiated HCCs (0.25 ± 0.07; p = 0.006). In conclusion this study suggests that the uptake of Gd-EOB-DTPA in HCCs is correlated with tumor grade. Thus, Gd-EOB-DTPA-assisted T1 relaxometry can help to further differentiation of HCC.
(© 2021. The Author(s).)

Magn Reson Med. 2010 Aug;64(2):439-46. (PMID: 20665788)
Dtsch Arztebl Int. 2014 Feb 14;111(7):101-6. (PMID: 24622679)
Cancer Biol Ther. 2005 Aug;4(8):815-8. (PMID: 16210916)
Sci Rep. 2017 Mar 07;7:43347. (PMID: 28266528)
Radiology. 2017 Feb;282(2):408-417. (PMID: 27697007)
Eur Radiol. 2008 Mar;18(3):457-67. (PMID: 18058107)
Acta Radiol. 2016 Aug;57(8):932-8. (PMID: 26586852)
Ann Surg. 2011 Jan;253(1):166-72. (PMID: 21294289)
Drug Metab Pharmacokinet. 2008;23(5):347-55. (PMID: 18974612)
J Hepatol. 2001 Apr;34(4):570-5. (PMID: 11394657)
Drug Metab Dispos. 2010 Jul;38(7):1024-8. (PMID: 20406852)
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22. (PMID: 15042359)
Invest Radiol. 2010 Mar;45(3):133-41. (PMID: 20098330)
J Magn Reson Imaging. 1996 May-Jun;6(3):472-7. (PMID: 8724413)
Liver Transpl. 2002 Dec;8(12):1165-74. (PMID: 12474157)
AJR Am J Roentgenol. 2009 Jun;192(6):1675-81. (PMID: 19457834)
BMC Cancer. 2016 Aug 12;16:625. (PMID: 27520833)
Clin Pharmacol Ther. 2007 Feb;81(2):194-204. (PMID: 17192770)
Magn Reson Med. 2003 Mar;49(3):515-26. (PMID: 12594755)
Eur J Radiol Open. 2020 Dec 24;8:100312. (PMID: 33392362)
Liver Transpl. 2011 Oct;17 Suppl 2:S14-25. (PMID: 21744470)
J Gastroenterol. 2009;44 Suppl 19:112-8. (PMID: 19148804)
J Gastroenterol. 2009;44(7):793-8. (PMID: 19404564)
AJR Am J Roentgenol. 2009 Oct;193(4):1053-60. (PMID: 19770329)
Liver Transpl. 2007 Nov;13(11 Suppl 2):S17-23. (PMID: 17969095)
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
Front Med (Lausanne). 2017 Nov 10;4:193. (PMID: 29209611)
Liver Int. 2005 Apr;25(2):367-79. (PMID: 15780063)
Radiology. 2010 Jun;255(3):824-33. (PMID: 20501720)
Abdom Imaging. 2014 Dec;39(6):1202-12. (PMID: 24869790)
Gastroenterology. 2001 Jun;120(7):1689-99. (PMID: 11375950)
Liver Transpl. 2000 Jan;6(1):67-72. (PMID: 10648580)
Transpl Int. 2003 Feb;16(2):115-22. (PMID: 12595973)
Sci Rep. 2015 Oct 19;5:15408. (PMID: 26478097)
Ann Surg. 2004 Feb;239(2):150-9. (PMID: 14745321)
N Engl J Med. 1996 Mar 14;334(11):693-9. (PMID: 8594428)
Radiology. 2013 Jun;267(3):776-86. (PMID: 23401584)
Arch Surg. 2001 Jan;136(1):25-30; discussion 31. (PMID: 11146770)
Hepatology. 2001 May;33(5):1080-6. (PMID: 11343235)
Biomedicines. 2020 Oct 13;8(10):. (PMID: 33066169)
Rofo. 2015 Oct;187(10):863-71. (PMID: 26230140)
J Magn Reson Imaging. 2001 Mar;13(3):397-401. (PMID: 11241813)
Radiology. 2005 Feb;234(2):468-78. (PMID: 15591431)
N Engl J Med. 2011 Sep 22;365(12):1118-27. (PMID: 21992124)
BMC Cancer. 2019 Apr 18;19(1):364. (PMID: 30999947)
Liver. 1987 Feb;7(1):18-26. (PMID: 3033422)
J Hepatol. 2016 Mar;64(3):708-16. (PMID: 26632635)
Med Clin (Barc). 2018 May 23;150(10):390-397. (PMID: 29096967)
J Biol Chem. 1999 Jun 11;274(24):17159-63. (PMID: 10358072)
J Hepatol. 2001 Apr;34(4):603-5. (PMID: 11394662)
Hepatology. 2005 Nov;42(5):1208-36. (PMID: 16250051)
J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. (PMID: 12490595)
Int J Cancer. 2001 Nov;94(4):492-9. (PMID: 11745434)
Z Gastroenterol. 2013 Nov;51(11):1269-326. (PMID: 24243572)
Ann Surg. 2007 Mar;245(3):435-42. (PMID: 17435551)
J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):1029-1036. (PMID: 29254310)

0 (Contrast Media)
0 (gadolinium ethoxybenzyl DTPA)
K2I13DR72L (Gadolinium DTPA)

Date Created: 20211127 Date Completed: 20220131 Latest Revision: 20220131

20250114

PMC8626433

10.1038/s41598-021-02499-2

34837039